Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: PK-based Hydroxyurea Dosing in Children With Sickle Cell Anemia
NCT05662098Phase 1Active, not recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydroxyurea in sickle cell anemia (SCA), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Rate of blood transfusions overall and by specific indications at 15 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
hydroxyurea
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT05662098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662098.